Koonohi
22 hours ago
The whole he said she said, DEA leak to a prohibitionist group is immaterial and will be found immaterial in the hearing to reschedule cannabis. I think the cannabis proponents are barking up the wrong tree there. Even in the worse case scenario, where the DEA conspires with prohibitionists to suddenly change position later on down the road to oppose rescheduling preemptively that is discovered later on through the freedom of information act, is immaterial because everyone present in the hearing has that right, to change their position!!!!!! That's why this whole he said she said is really immaterial and the primary focus and energy input should be on the MATERIAL arguments to reschedule cannabis. All else is truly secondary and is something I think a lot of pro cannabis rescheduling advocates just can't comprehend as they jostle for the upper hand, they stamp each other out and frankly, that's really tragic and ironic. Can you imagine what could happen if the cannabis advocates put the same amount of time and energy they put into their conspiracy theory into arguing their case with material evidence, facts, expert witnesses would be?
Koonohi
3 days ago
Has anyone noticed MJNA's financials since the 2018 farm bill that essentially legalized hemp? They've lost a great deal of market share since then. And in that time, their financials reveal declining revenues, as, it seems, more and more people sell and make cheap CBD products since CBD as a medicine or a nutritional supplement is not at all regulated. Meanwhile, MJNA continues their patented expensive testing of their products and more but, their operating expenses/COGS has also declined alongside revenues so, it's a good thing they didn't over extend themselves, (like medmen did). Still, declining revenues year over year in an ever increasingly competitive CBD market that is largely unregulated is cringe worthy for sure since there is very little to attract market share to a bunch of nerdy old doctors and their products, (sorry, I'm not tryna' be rude just tryna' cut to the chase and I happen to like nerdy old doctors but, I'm odd). Anyway, what kind of language do you suppose will benefit MJNA in this next farm bill (that is currently on the table and being negotiated that will carry over for six years or so to come)? Do you think regulation of CBD is a good idea in the interests of consumer safety? Just curious.
Koonohi
3 days ago
Back in on MJNA. Actually, I never left. I been long with this company since 2014/15 give or take a few. I figure I can hang on another five years. No big deal. So, long as I got other stuff going on. In the meantime, I been loading up on some shares here and there. I figure there is a very real possibility MJNA could plummet to .0001 per share so, I got reserves on standby. But, loading up is easy on the OTC, offloading is the hard part when there are no buyers so, that indicates a lack of interest in this stock and industry as a whole. Even GTBIF, despite turning a profit, is down significantly with some saying it has an upside potential of 75%! So, the cannabis industry as a whole, (including MJNA), is largely ignored at the moment by most investors who want real and tangible change in the regulatory/political environment, because without it, future profitability analytics are too fuzzy to make sense. Anyway, MJNA is the least popular stock discussed and traded today along with all the other trail blazer stocks of yesteryear. Thankfully, they seem to have a fairly good business model that keeps them afloat until regulations, (which could take two years or more), turn in their favor. Anyway you look at it, this stock is risky business. What do you think?
Saving Grace
4 days ago
DEA to Hold Hearing on the Rescheduling of Marijuana
MEDIA ADVISORY
DEA Headquarters Division - Public Information Office
WASHINGTON – Formal hearing proceedings regarding the proposed rescheduling of marijuana will begin on December 2, 2024 at 9:30 A.M. ET in the North Courtroom at DEA Headquarters located at 700 Army Navy Drive, Arlington, VA. This preliminary hearing will serve as a procedural day to address legal and logistical issues and discuss future dates for the evidentiary hearing on the merits. No witness testimony will be offered or received at this time.
In-person attendance is limited to designated participants and credentialed members of the media who have received confirmation of their in-person attendance.
WHAT: Commencement of formal hearing proceedings regarding the proposed rescheduling of Marijuana
WHO: Open to designated participants and designated credentialed members of the media.
WHEN: December 2, 2024 | 9:30 a.m. to 5 p.m.
WHERE: DEA Headquarters | 700 Army Navy Drive, Arlington, Va. 22202 | North Courtroom
FOR MEMBERS OF THE PUBLIC: Members of the public will have access to the court sessions virtually at www.DEA.gov/live.
FOR NEWS MEDIA: News media wishing to attend in person must RSVP to DEAPress@dea.gov by 10 a.m. on November 29, 2024. Due to limited capacity, RSVPs will be accepted on a first come, first served basis.
Designated members of the media should arrive no later than 9:00 a.m. on December 2 and follow all security screening procedures. Media credentials are required to be visible while inside DEA Headquarters. Video and audio recordings are not permitted at any time inside the courtroom.
Background:
On May 21, 2024, the Department of Justice proposed to transfer marijuana from schedule I of the Controlled Substances Act to schedule III of the CSA, consistent with the view of the Department of Health and Human Services that marijuana has a currently accepted medical use as well as HHS's views about marijuana's abuse potential and level of physical or psychological dependence. The CSA requires that such actions be made through formal rulemaking on the record after opportunity for a hearing. If the transfer to schedule III is finalized, the regulatory controls applicable to schedule III controlled substances would apply, as appropriate, along with existing marijuana-specific requirements and any additional controls that might be implemented, including those that might be implemented to meet U.S. treaty obligations. If marijuana is transferred into schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to the applicable criminal prohibitions of the CSA. Any drugs containing a substance within the CSA's definition of “marijuana” would also remain subject to the applicable prohibitions in the Federal Food, Drug, and Cosmetic Act. For more information, visit www.DEA.gov.
https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana